<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03237325</url>
  </required_header>
  <id_info>
    <org_study_id>IDR-OM-02</org_study_id>
    <nct_id>NCT03237325</nct_id>
  </id_info>
  <brief_title>DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer</brief_title>
  <official_title>A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soligenix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soligenix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe
      oral mucositis in patients receiving chemoradiation treatment for the treatment of head and
      neck cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of severe oral mucositis (SOM)</measure>
    <time_frame>approx. 13 weeks</time_frame>
    <description>To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis (SOM; defined as World Health Organization [WHO] Grade ≥3). Duration of SOM is defined as the number of days from the onset of SOM until resolution of SOM. OM is evaluated using the published WHO OM grading scale that uses a scale of 0 to 4, with SOM defined as a score ≥3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity-weighted duration of SOM by Area-Under-the-Curve (AUC) for the WHO Grade ≥3 by time plot</measure>
    <time_frame>approx. 13 weeks</time_frame>
    <description>To assess the impact of SGX942 on the severity-weighted duration of SOM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of SOM</measure>
    <time_frame>approx. 13 weeks</time_frame>
    <description>To assess the impact of SGX942 compared to placebo on duration of SOM; in all randomized patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ulcerative OM</measure>
    <time_frame>approx. 13 weeks</time_frame>
    <description>To assess the impact of SGX942 compared to placebo on the duration of ulcerative OM (UOM; defined as WHO Grade ≥2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SOM</measure>
    <time_frame>approx. 13 weeks</time_frame>
    <description>To assess the impact of SGX942 compared to placebo on the incidence of SOM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of radiation treatment (RT) breaks</measure>
    <time_frame>approx. 9 weeks</time_frame>
    <description>To assess the impact of SGX942 compared to placebo on the number RT breaks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RECIST categorization of the primary tumor</measure>
    <time_frame>approx. 11 weeks</time_frame>
    <description>To assess the impact of SGX942 compared to placebo on RECIST (Response Evaluation Criteria In Solid Tumors) categorization of the primary tumor at 4 weeks after completion of RT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of reported presumed bacterial infections</measure>
    <time_frame>approx. 13 weeks</time_frame>
    <description>To assess the impact of SGX942 compared to placebo on incidence of reported presumed bacterial infections between Baseline and 6 weeks after completion of RT by total number and by severity of infection, graded using the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Squamous Cell Carcinoma of the Oral Cavity and Oropharynx</condition>
  <condition>Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>SGX942</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized 1:1 active/placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients are randomized 1:1 active/placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGX942</intervention_name>
    <description>1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.</description>
    <arm_group_label>SGX942</arm_group_label>
    <other_name>Dusquetide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven squamous cell carcinoma of the oral cavity or oropharynx without distant
             organ metastases

          -  Scheduled to receive cisplatin chemotherapy of 80-100 mg/m²

          -  Scheduled to receive a continuous course of fractionated, conventional external beam
             with a cumulative radiation dose between 55 and 72 Gy at each site

        Exclusion Criteria:

          -  Current mucositis

          -  Current, clinically significant, active infection that in the opinion of the
             Investigator would make them an unfit participant in the trial

          -  Planned to receive Erbitux™ (Cetuximab) or similar targeted therapy between Baseline
             and 6 weeks post-RT

          -  Prior radiation to the head and neck

          -  Chemotherapy treatment within the previous 12 months

          -  Tumors of the lips, sinuses, salivary glands, nasopharynx, hypopharynx, or larynx

          -  Evidence of significant renal, hepatic, hematologic, or immunologic disease determined
             by any one of the following: Estimated creatinine clearance &lt;30 mL/min; ALT or AST
             level greater than 10-fold the upper limit of normal or total bilirubin greater than
             3-fold the upper limit of normal; Manifestations of end-stage liver disease, such as
             ascites or hepatic encephalopathy; Thrombocytopenia; or CD4+ T cell count below 200
             cells per μL

          -  Evidence of immediate life-threatening disease or a life expectancy of less than 3
             months

          -  Women who are pregnant or breast-feeding

          -  Participation in any study involving administration of an investigational agent within
             30 days of randomization into this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher Pullion, DO</last_name>
    <phone>609-538-8200</phone>
    <phone_ext>23</phone_ext>
    <email>cpullion@soligenix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Richard Straube, MD</last_name>
    <phone>609-538-8200</phone>
    <phone_ext>30</phone_ext>
    <email>rstraube@soligenix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Broward Health Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Borus</last_name>
      <email>Lborus@browardhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pasco Pinellas Cancer Center</name>
      <address>
        <city>Holiday</city>
        <state>Florida</state>
        <zip>34691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Kisko</last_name>
      <email>dkisko@tampabay.rr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Illinois Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Secreto</last_name>
      <email>asecre2@uic.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Vollstedt</last_name>
      <phone>319-353-7143</phone>
      <email>sandy-vollstedt@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Brown</last_name>
      <phone>319-384-7912</phone>
      <email>heather-brown@uiowa.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise Tatje</last_name>
      <email>etatje@tulane.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Willis Knighton Cancer Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Briana Barrow</last_name>
      <phone>318-212-8671</phone>
      <email>bbarrow@wkhs.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Marchlewicz</last_name>
      <email>marchlei@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Missouri-Ellis Fischel Cancer Center</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troy Twyman</last_name>
      <email>twymane@health.missouri.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional-Gibbs Cancer Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luann Lester</last_name>
      <email>LLester@gibbscc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Research Institute</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gates Anderson</last_name>
      <phone>254-724-5889</phone>
      <email>Gates.Anderson@BSWHealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>North JR, Takenaka S, Rozek A, Kielczewska A, Opal S, Morici LA, Finlay BB, Schaber CJ, Straube R, Donini O. A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy. J Biotechnol. 2016 May 20;226:24-34. doi: 10.1016/j.jbiotec.2016.03.032. Epub 2016 Mar 23.</citation>
    <PMID>27015977</PMID>
  </reference>
  <reference>
    <citation>Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis ST, Straube R, Donini O. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016 Dec 10;239:115-125. doi: 10.1016/j.jbiotec.2016.10.010. Epub 2016 Oct 13.</citation>
    <PMID>27746305</PMID>
  </reference>
  <reference>
    <citation>Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Scott Z, Elder J, Sonis ST, Straube R, Donini O. Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotechnol Rep (Amst). 2017 May 17;15:24-26. doi: 10.1016/j.btre.2017.05.002. eCollection 2017 Sep.</citation>
    <PMID>28649557</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2017</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OM</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>SGX942</keyword>
  <keyword>Dusquetide</keyword>
  <keyword>Squamous Cell Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

